A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

about

Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O-methylguanine-DNA methyltransferase with a double arm hybrid molecule

P2860

Q58738665-3B0D3436-CB72-4415-A9FA-EB434A74ECF7

P2860

A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

Item

http://www.wikidata.org/entity/Q41365343

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

A type I combi-targeting appro ...... mgmt)- expressing tumour cells

@en

type

Item

label

A type I combi-targeting appro ...... mgmt)- expressing tumour cells

@en

prefLabel

A type I combi-targeting appro ...... mgmt)- expressing tumour cells

@en

P1476

A type I combi-targeting appro ...... mgmt)- expressing tumour cells

@en

P2093

Elliot Goodfellow

http://www.w3.org/2001/XMLSchema#string

Zhor Senhaji Mouhri

http://www.w3.org/2001/XMLSchema#string

P2860

New colorimetric cytotoxicity assay for anticancer-drug screening

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy.

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.

Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents.

Carbohydrate recognition by boronolectins, small molecules, and lectins.

Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.

Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting

P2888

s12885-017-3504-1

P304

540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-017-3504-1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bertrand Jean-Claude

P577

2017-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091167097

http://www.w3.org/2001/XMLSchema#string

P698

28800752

http://www.w3.org/2001/XMLSchema#string

P921

DNA design

P932

5553999

http://www.w3.org/2001/XMLSchema#string

A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

about

P2860

P2860

A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P921

P932